Rupert D'Souza is CFO at Adverum Biotechnologies, Inc. (ADVM). They have made 1 open-market trade across 1 company since 2022, most recently 2022-05-17.
CIK 0001897112
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $17K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADVM | 10,850 | $47K |
Shares reported on the most recent Form 4, priced at the 2022-05-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADVM | BUY | 2022-05-13 | 2022-05-17 | $0.85 | $17K | +5.1% | +14.8% | +66.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.